Basic Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2020; 12(10): 1091-1103
Published online Oct 15, 2020. doi: 10.4251/wjgo.v12.i10.1091
Synergistic anti-liver cancer effects of curcumin and total ginsenosides
Zhe Deng, Xiao-Yan Xu, Fenny Yunita, Qing Zhou, Yong-Rong Wu, Yu-Xing Hu, Zhi-Qi Wang, Xue-Fei Tian
Zhe Deng, Fenny Yunita, Xue-Fei Tian, Department of Internal Medicine, College of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Xiao-Yan Xu, Xue-Fei Tian, Hunan Key Laboratory of Translational Research in Formulas and Zheng of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Qing Zhou, The First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Yong-Rong Wu, Yu-Xing Hu, School of Basic Chinese Medical Sciences, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Zhi-Qi Wang, College of Pharmaceutical Sciences, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Author contributions: Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, and Wang ZQ performed the experiments; Deng Z and Xu XY reviewed and edited the manuscript; Deng Z, Xu XY, and Yunita F designed and performed the study, conducted the statistical analysis, and wrote the paper; Tian XF conceived and designed the study. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy and integrity of any part of the work are appropriately investigated and resolved.
Supported by the National Natural Science Foundation of China, No. 81473617; the Science and Technology Department of Hunan Province, No. 2017SK50310; and the Hunan Education Department’s Science and Research Project, No. 16K066.
Institutional animal care and use committee statement: This study was reviewed and approved by the Ethics Review Committee of Experimental Animal Welfare at the Central South University in Changsha, China.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: Dataset available from the corresponding author at 003640@hnucm.edu.cn. The participants gave informed consent for data sharing.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xue-Fei Tian, PhD, Professor, College of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, 300 Xueshi Road, Yuelu District, Changsha 410208, Hunan Province, China. 003640@hnucm.edu.cn
Received: March 2, 2020
Peer-review started: March 2, 2020
First decision: April 25, 2020
Revised: May 18, 2020
Accepted: May 27, 2020
Article in press: May 27, 2020
Published online: October 15, 2020
Processing time: 226 Days and 1.6 Hours
Core Tip

Core Tip: The occurrence and development of liver cancer can be driven by inflammation, and the imbalance of cell-mediated immune mechanism also plays an important role. Controlling inflammation and restoring cellular immunity are new targets for the treatment of liver cancer. Here, we combined curcumin, an effective drug that controls inflammation, with total ginsenosides, which enhance immune function. We confirmed that the two drugs had a synergistic anti-liver cancer effect in a mouse model of subcutaneous, and they played their roles mainly through programmed cell death 1 ligand 1 and NF-κB signaling pathway. These findings provide a new idea for combined drug therapy for liver cancer.